ArticleFrontiers in medicine2025
Molecular signatures of alveolar type II cell differentiation in acute respiratory distress syndrome.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MicroRNA-18a-3p as a biomarker for neonatal respiratory distress syndrome and its effects in alveolar epithelial type II cells.BMC immunology · 2026Article
- Mitochondrial-related biomarkers as the diagnostic markers in sepsis induced acute respiratory distress syndrome.European journal of medical research · 2026Article
- Astaxanthin Reverses Oxidative Stress-Induced Dysfunction in Human Periodontal Ligament Stem Cells by Activating the Nrf2/ARE Pathway.Stem cells international · 2026Article
- The single-cell immune atlas of bacterial pneumonia: from inflammatory cell infiltration to treatable cell states.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute respiratory distress syndrome (ARDS) is a life-threatening lung condition with high morbidity and mortality. Methods: We analyzed publicly available single-cell transcriptomic and microarray datasets from murine ARDS models to characterize AT2 cell differentiation trajectories following lipopolysaccharide (LPS)-induced injury. Computational mapping of cell "trajectories" revealed distinct gene expression signatures associated with divergent repair outcomes. These findings were validated in bronchoalveolar lavage fluid (BALF) samples from ARDS patients and in an LPS-induced AT2-fibroblast co-culture model. Gene expression changes were examined at both the RNA and protein levels, and pathway enrichment analysis was used to explore underlying mechanisms. Results: Trajectory analysis revealed two major differentiation branches of AT2 cells: one enriched for fibrotic programs (Igfbp6, Gstm1, Mgp, and Lgals1) and the other linked to epithelial repair (Tgm2, Anxa1, Ankrd1, and F3). Both branches exhibited distinct gene expression patterns in patient BALF, which was consistent with scRNA-seq findings. Functional enrichment highlighted the Wnt signaling pathway as a key regulator in the injury group, which was validated at protein levels Conclusion: This study highlights the important role of AT2 cell differentiation in shaping disease progression in ARDS and identifies potential molecular markers and signaling pathways involved in divergent repair outcomes. Our findings provide new insight into AT2 cell-driven lung repair and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.